In conclusion, the combination of peripheral T cell cytotoxicity and the peripheral CD45RA+CD25+/CD4+ T cell ratio predicted the efficacy and severe AEs of anti-PD-1 therapy for advanced NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.